0R3M Stock Chart & Stats
€1.14
€0.03(2.56%)
At close: 4:00 PM EDT
€1.14
€0.03(2.56%)
Day’s Range― - ―
52-Week Range€1.02 - €1.82
Previous CloseN/A
Volume7.00
Average Volume (3M)364.00
Market Cap
€32.58M
Enterprise Value€29.61
Total Cash (Recent Filing)€2.45M
Total Debt (Recent Filing)€76.00K
Price to Earnings (P/E)―
Beta0.35
Next Earnings
Dec 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.5%
Share Statistics
EPS (TTM)-0.23
Shares Outstanding29,614,338
10 Day Avg. Volume1,066
30 Day Avg. Volume364
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)8.11
Price to Sales (P/S)0.00
P/FCF Ratio-4.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.32
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageMinimal debt reduces mandatory financing costs and near-term creditor pressure compared with a highly leveraged biotech. This gives management greater flexibility to allocate limited resources toward clinical development, although the benefit is tempered by the company’s small and declining equity base.
Reduced Annual LossThe substantial year-over-year reduction in net loss indicates some progress in controlling expenses or reducing development burden. If sustained, lower losses could extend the company’s funding runway and reduce the scale of external capital required to advance its clinical programs.
Oral Small-Molecule PlatformAn orally available lead candidate and related discovery capabilities provide a coherent platform for developing multiple therapeutics rather than relying on a single unrelated asset. This may support broader partnering or pipeline opportunities if clinical data validates the underlying biology.
Bears Say
No Recent Operating RevenueThe absence of recent revenue means the company has not demonstrated a self-funding commercial model and remains dependent on financing or potential licensing proceeds. Without product sales, future development spending is not supported by recurring operating inflows.
Persistent Negative Cash FlowContinued operating and free-cash-flow deficits show that the business currently consumes cash rather than generating it. Even with improved burn, ongoing clinical and corporate costs are likely to require external funding, creating dilution or balance-sheet contraction risk.
Shrinking Equity And Asset BaseThe sharp contraction in equity and total assets signals that cumulative losses have materially reduced financial resources. A smaller capital base limits flexibility to absorb setbacks, sustain clinical programs, or pursue new opportunities without obtaining additional funding.
Vivoryon Therapeutics AG News
0R3M FAQ
What was Vivoryon Therapeutics AG’s price range in the past 12 months?
Vivoryon Therapeutics AG lowest share price was €1.02 and its highest was €1.82 in the past 12 months.
What is Vivoryon Therapeutics AG’s market cap?
Vivoryon Therapeutics AG’s market cap is €32.58M.
When is Vivoryon Therapeutics AG’s upcoming earnings report date?
Vivoryon Therapeutics AG’s upcoming earnings report date is Dec 03, 2026 which is in 62 days.
How were Vivoryon Therapeutics AG’s earnings last quarter?
Vivoryon Therapeutics AG released its earnings results on Aug 06, 2026. The company reported -€0.114 earnings per share for the quarter.
Is Vivoryon Therapeutics AG overvalued?
According to Wall Street analysts Vivoryon Therapeutics AG’s price is currently Overvalued.
Does Vivoryon Therapeutics AG pay dividends?
Vivoryon Therapeutics AG pays a Notavailable dividend of €0.285 which represents an annual dividend yield of 2.5%. See more information on Vivoryon Therapeutics AG dividends here
What is Vivoryon Therapeutics AG’s EPS estimate?
Vivoryon Therapeutics AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vivoryon Therapeutics AG have?
Vivoryon Therapeutics AG has 29,614,338 shares outstanding.
What happened to Vivoryon Therapeutics AG’s price movement after its last earnings report?
Vivoryon Therapeutics AG reported an EPS of -€0.114 in its last earnings report. Following the earnings report the stock price went up 2.966%.
Which hedge fund is a major shareholder of Vivoryon Therapeutics AG?
Currently, no hedge funds are holding shares in GB:0R3M
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vivoryon Therapeutics AG
Vivoryon Therapeutics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel treatments for Alzheimer's disease. The company's therapeutic pipeline primarily focuses on mitigating Alzheimer's by targeting and preventing the formation of toxic pyroglutamate-Abeta (pGlu-Abeta). Its flagship compound, PQ912, a small molecule QC inhibitor, has successfully concluded Phase IIb clinical trials for both Alzheimer's disease and various cancer indications. Additionally, Vivoryon is advancing PQ1565, another small molecule (a glutaminyl-peptide cyclotransferase-like inhibitor), through preclinical development, specifically for cancer therapy. Beyond its small molecule programs, the company is also developing a monoclonal antibody designed to improve the clearance of pGlu-Abeta from the body. To bolster its research and development efforts, Vivoryon has forged several key partnerships, including collaborations with the University Medical Center Schleswig-Holstein for cancer immunotherapy discovery, Nordic Bioscience for the clinical progression of PQ912 in Alzheimer's, and the Fraunhofer Institute for cell therapy and immunology. Furthermore, a significant regional licensing agreement with Simcere Pharmaceutical Group Ltd. aims to develop and commercialize treatments for Alzheimer's disease by targeting the neurotoxic amyloid species N3pE (pGlu-Abeta). Established in 1997, Vivoryon Therapeutics N.V. maintains its headquarters in Halle, Germany.
Technical Analysis
Pharming Group
―
Avantium N.V.
―
Corbion NV
―
Lakefront Biotherapeutics NV
―
DSM-Firmenich AG
―